ARVN vs. SNDX, AKRO, MORF, RYTM, PLRX, RVMD, ELAN, SMMT, KRYS, and OGN
Should you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include Syndax Pharmaceuticals (SNDX), Akero Therapeutics (AKRO), Morphic (MORF), Rhythm Pharmaceuticals (RYTM), Pliant Therapeutics (PLRX), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Summit Therapeutics (SMMT), Krystal Biotech (KRYS), and Organon & Co. (OGN). These companies are all part of the "medical" sector.
Arvinas (NASDAQ:ARVN) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings, community ranking and institutional ownership.
Arvinas currently has a consensus target price of $61.13, suggesting a potential upside of 106.18%. Syndax Pharmaceuticals has a consensus target price of $34.73, suggesting a potential upside of 41.80%. Given Arvinas' higher possible upside, analysts plainly believe Arvinas is more favorable than Syndax Pharmaceuticals.
Syndax Pharmaceuticals received 200 more outperform votes than Arvinas when rated by MarketBeat users. However, 65.40% of users gave Arvinas an outperform vote while only 64.92% of users gave Syndax Pharmaceuticals an outperform vote.
In the previous week, Arvinas had 1 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 5 mentions for Arvinas and 4 mentions for Syndax Pharmaceuticals. Arvinas' average media sentiment score of 0.62 beat Syndax Pharmaceuticals' score of 0.58 indicating that Arvinas is being referred to more favorably in the media.
Arvinas has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.
95.2% of Arvinas shares are owned by institutional investors. 5.2% of Arvinas shares are owned by insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Syndax Pharmaceuticals' return on equity of -53.32% beat Arvinas' return on equity.
Syndax Pharmaceuticals has higher revenue and earnings than Arvinas. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.
Summary
Arvinas beats Syndax Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Arvinas News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
